Technical Analysis for BMY - Bristol-Myers Squibb Company

Grade Last Price % Change Price Change
A 68.34 0.00% 0.00
BMY closed up 0.56 percent on Friday, July 23, 2021, on 80 percent of normal volume. The bulls were able to push the stock to a new 52-week high. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Earnings due: Jul 28
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical BMY trend table...

Date Alert Name Type % Chg
MACD Bullish Signal Line Cross Bullish 0.00%
New 52 Week Closing High Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
New 52 Week High Strength 0.00%
Stochastic Reached Overbought Strength 0.00%
BB Squeeze + Upper Band Touch Range Contraction 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Older End-of-Day Signals for BMY ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Bristol-Myers Squibb Company Description

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Its principal products include Plavix for protection against fatal or non-fatal heart attack or stroke; Avapro/Avalide for the treatment of hypertension and diabetic nephropathy; Eliquis to prevent and treat venous thromboembolic disorders and stroke prevention in atrial fibrillation; Abilify, an agent for adult patients with schizophrenia, bipolar mania disorder, and depressive disorder; and Reyataz and Sustiva to treat human immunodeficiency virus. The company's products also include Baraclude, an inhibitor of hepatitis B virus; Erbitux to target and block the epidermal growth factor receptor; Sprycel for treatment of chronic myeloid leukemia in adults; Yervoy to treat metastatic melanoma; Orencia to treat adult patients with moderate to severe rheumatoid arthritis; Nulojix to prevent kidney transplant rejection; Onglyza/Kombiglyze, Byetta, and Bydureon to treat type 2 diabetes; and Forxiga for the treatment of diabetes. Its products under Phase III clinical trials include Asunaprevir and Daclatasvir, which are oral small molecule to treat hepatitis C virus infection; Peginterferon lambda, a novel type 3 interferon for hepatitis C virus infection; Elotuzumab for multiple myeloma; and Nivolumab, an anticancer treatment, as well as products under the registrational process comprises Metreleptin for the treatment of lipodystrophy. The company sells its products to wholesalers, as well as directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: S&P 500 Biopharmaceutical Clinics Diabetes Pharmaceutical Products Hypertension Melanoma Rheumatoid Arthritis Schizophrenia Hepatitis B Cancer Treatment Multiple Myeloma Stroke Dystrophy Serious Diseases Organic Chemistry Epidermal Growth Factor Receptor Depressive Disorder Hepatitis C Immunodeficiency Hepatitis B Virus Hepatitis C Virus Biopharmaceutical Products Diabetic Nephropathy Treatment Of Diabetes Atrial Fibrillation Interferon Metastatic Melanoma Heart Attack Hepatitis C Virus Infection Kidney Transplant Transplant Rejection Chronic Myeloid Leukemia Leptin Lipodystrophy Treatment Of Hypertension

Is BMY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 68.53
52 Week Low 56.75
Average Volume 8,717,088
200-Day Moving Average 63.39
50-Day Moving Average 66.41
20-Day Moving Average 67.07
10-Day Moving Average 67.41
Average True Range 0.93
ADX 15.66
+DI 27.75
-DI 15.90
Chandelier Exit (Long, 3 ATRs) 65.73
Chandelier Exit (Short, 3 ATRs) 68.04
Upper Bollinger Bands 68.18
Lower Bollinger Band 65.97
Percent B (%b) 1.07
BandWidth 3.29
MACD Line 0.39
MACD Signal Line 0.34
MACD Histogram 0.0522
Fundamentals Value
Market Cap 154.43 Billion
Num Shares 2.26 Billion
EPS 0.51
Price-to-Earnings (P/E) Ratio 133.22
Price-to-Sales 3.46
Price-to-Book 2.78
PEG Ratio 0.82
Dividend 1.80
Dividend Yield 2.63%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 69.42
Resistance 3 (R3) 69.36 68.95 69.24
Resistance 2 (R2) 68.95 68.67 68.98 69.18
Resistance 1 (R1) 68.64 68.50 68.80 68.70 69.12
Pivot Point 68.23 68.23 68.30 68.26 68.23
Support 1 (S1) 67.92 67.95 68.08 67.98 67.56
Support 2 (S2) 67.51 67.78 67.54 67.50
Support 3 (S3) 67.20 67.51 67.44
Support 4 (S4) 67.26